Rasio cepet Regulus Therapeutics (RGLS)

Current price action for Regulus Therapeutics (RGLS) reflects the current 14.93 metric. The business relies on a patent portfolio that enables the rapid scaling of high-margin product manufacturing via third-party contractors. The team consists of scientists attracted by the freedom to study cellular structures and stock options. Regulus Therapeutics (RGLS) is currently in a high-burn phase, as commercial products have not yet been brought to market.

Cash reserves are critical for Regulus Therapeutics (RGLS), as its success depends on RNA therapy clinical trials rather than market cycles. This metric measures the company's ability to immediately cover short-term debts using only cash and accounts receivable, excluding illiquid inventories. This quick ratio chart allows for the tracking of cash gap risks or excessive capital idling. The stability of this indicator confirms the financial resilience of the company's R&D processes.